Sirolimus Can Increase the Disappearance Rate of Cardiac Rhabdomyomas Associated with Tuberous Sclerosis: A Prospective Cohort and Self-Controlled Case Series StudyXiao-Qiao Chen, Li‐Ping Zou, Yangyang Wang et al.|The Journal of Pediatrics|2021Cited by 24
Sirolimus treatment for tuberous sclerosis complex prior to epilepsy: Evidence from a registry-based real-world studyYan-Wen Shen, Li‐Ping Zou, Yong Xu et al.|Seizure|2022Cited by 22
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysisYang‐Yang Wang, Yufen Li, Li‐Ping Zou et al.|Orphanet Journal of Rare Diseases|2024Cited by 11
Safety Profile of Sirolimus in All Age Groups: A Pooled Analysis of Two 10-Year Cohort Studies Comprising 1738 Patients With Tuberous Sclerosis and/or LymphangioleiomyomatosisLi‐Ping Zou, Yufen Li, Yangyang Wang et al.|SSRN Electronic Journal|2021Cited by 0